193 related articles for article (PubMed ID: 21922147)
1. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer.
Kasuya K; Tsuchida A; Nagakawa Y; Suzuki M; Abe Y; Itoi T; Serizawa H; Nagao T; Shimazu M; Aoki T
Oncol Rep; 2011 Dec; 26(6):1399-406. PubMed ID: 21922147
[TBL] [Abstract][Full Text] [Related]
2. IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer.
Zhao T; Jin F; Xiao D; Wang H; Huang C; Wang X; Gao S; Liu J; Yang S; Hao J
Theranostics; 2020; 10(9):4088-4100. PubMed ID: 32226541
[TBL] [Abstract][Full Text] [Related]
3. PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer.
Liu YF; Luo D; Li X; Li ZQ; Yu X; Zhu HW
Pancreas; 2021 Feb; 50(2):227-234. PubMed ID: 33565800
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
Wang R; Cheng L; Xia J; Wang Z; Wu Q; Wang Z
Curr Cancer Drug Targets; 2014; 14(4):407-17. PubMed ID: 24575976
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells.
He X; Wang J; Wei W; Shi M; Xin B; Zhang T; Shen X
Cancer Biol Ther; 2016; 17(2):188-98. PubMed ID: 26785721
[TBL] [Abstract][Full Text] [Related]
7. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization.
Luo B; Song L; Chen L; Cai Y; Zhang M; Wang S
Phytomedicine; 2024 Jul; 129():155675. PubMed ID: 38678954
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.
Schwartz DL; Bankson JA; Lemos R; Lai SY; Thittai AK; He Y; Hostetter G; Demeure MJ; Von Hoff DD; Powis G
Mol Cancer Ther; 2010 Jul; 9(7):2057-67. PubMed ID: 20587661
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblasts promote stemness maintenance and gemcitabine resistance via HIF-1α/miR-21 axis under hypoxic conditions in pancreatic cancer.
Deng K; Zou F; Xu J; Xu D; Luo Z
Mol Carcinog; 2024 Mar; 63(3):524-537. PubMed ID: 38197482
[TBL] [Abstract][Full Text] [Related]
10. The effect of HIF-1alpha siRNA on growth and chemosensitivity of MIA-paca cell line.
Yang L; Kang WK
Yonsei Med J; 2008 Apr; 49(2):295-300. PubMed ID: 18452268
[TBL] [Abstract][Full Text] [Related]
11. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
[TBL] [Abstract][Full Text] [Related]
13. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.
Arora S; Bhardwaj A; Singh S; Srivastava SK; McClellan S; Nirodi CS; Piazza GA; Grizzle WE; Owen LB; Singh AP
J Biol Chem; 2013 Jul; 288(29):21197-21207. PubMed ID: 23740244
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.
Samulitis BK; Landowski TH; Dorr RT
Invest New Drugs; 2009 Feb; 27(1):89-98. PubMed ID: 18607542
[TBL] [Abstract][Full Text] [Related]
15. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
Iwahashi S; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Mori H; Hanaoka J; Sugimoto K; Saito Y
Int J Clin Oncol; 2011 Dec; 16(6):671-8. PubMed ID: 21556798
[TBL] [Abstract][Full Text] [Related]
17. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
18. Rg3 inhibits gemcitabine-induced lung cancer cell invasiveness through ROS-dependent, NF-κB- and HIF-1α-mediated downregulation of PTX3.
Ahmmed B; Kampo S; Khan M; Faqeer A; Kumar SP; Yulin L; Liu JW; Yan Q
J Cell Physiol; 2019 Jul; 234(7):10680-10697. PubMed ID: 30628067
[TBL] [Abstract][Full Text] [Related]
19. Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro.
Bosco G; Guizzon L; Yang Z; Camporesi E; Casarotto A; Bosio C; Mangar D; Chen C; Cannato M; Toniolo L; Garetto G; Nasole E; Bassi C
Anticancer Res; 2013 Nov; 33(11):4827-32. PubMed ID: 24222119
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in the hypoxia-inducible factor-1α gene confer susceptibility to pancreatic cancer.
Wang X; Liu Y; Ren H; Yuan Z; Li S; Sheng J; Zhao T; Chen Y; Liu F; Wang F; Huang H; Hao J
Cancer Biol Ther; 2011 Sep; 12(5):383-7. PubMed ID: 21709439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
